HR+ MBC: Palbociclib Plus Endocrine Therapy on Time to Chemotherapy
November 22nd 2021The rationale for conducting a post-hoc analysis of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor-positive metastatic breast cancer as presented at ESMO 2021.
Read More